Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction
- 11 January 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 167 (2), 188-194
- https://doi.org/10.1111/j.1365-2249.2011.04514.x
Abstract
Summary: OTHER THEMES PUBLISHED IN THIS IMMUNOLOGY IN THE CLINIC REVIEW SERIES Metabolic Diseases, Host Responses, Allergies, Autoinflammatory Diseases, Type 1 diabetes and viruses. Despite complex genomic and epigenetic abnormalities, many cancers are irrevocably dependent on an initiating oncogenic lesion whose restoration to a normal physiological activation can elicit a dramatic and sudden reversal of their neoplastic properties. This phenomenon of the reversal of tumorigenesis has been described as oncogene addiction. Oncogene addiction had been thought to occur largely through tumour cell-autonomous mechanisms such as proliferative arrest, apoptosis, differentiation and cellular senescence. However, the immune system plays an integral role in almost every aspect of tumorigenesis, including tumour initiation, prevention and progression as well as the response to therapeutics. Here we highlight more recent evidence suggesting that oncogene addiction may be integrally dependent upon host immune-mediated mechanisms, including specific immune effectors and cytokines that regulate tumour cell senescence and tumour-associated angiogenesis. Hence, the host immune system is essential to oncogene addiction.This publication has 86 references indexed in Scilit:
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte FunctionCancer Research, 2010
- Tumor Stroma-Derived TGF-beta Limits Myc-Driven Lymphomagenesis via Suv39h1-Dependent SenescenceCancer Cell, 2010
- Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T CellsJournal of Immunotherapy, 2010
- Adoptive immunotherapy of cancer using CD4+ T cellsCurrent Opinion in Immunology, 2009
- The tumour microenvironment as a target for chemopreventionNature Reviews Cancer, 2007
- Targeted cancer therapyNature, 2004
- Characterizing the Protective Component of the αβ T Cell Response to Transplantable Squamous Cell CarcinomaJournal of Investigative Dermatology, 2004
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Aids-related malignanciesNature Reviews Cancer, 2002
- Reversible Tumorigenesis by MYC in Hematopoietic LineagesMolecular Cell, 1999